名稱 | TIGIT/PVRIG Dual Effector Reporter Cell |
型號(hào) | CBP74167 |
報(bào)價(jià) | |
特點(diǎn) | TIGIT/PVRIG Dual Effector Reporter Cell |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74167TIGIT/PVRIG Dual Effector Reporter Cell
- 詳細(xì)內(nèi)容
CBP74167 | |
I. Background | |
TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies. PVRIG (CD112R) is an regulatory protein expressed on T-cells which inhibits immune activation when binding to its counterpart on APCs, PVRL2 (CD112, Nectin-2). Since both PVRL2 and PVR can activate DNAM-1 (CD226), PVRIG works synergistically with and separately from TIGIT. PVRL2 is overexpressed in a variety of tumor types, including breast and ovarian cancers, suggesting that its interaction with PVRIG is a major mechanism of immune suppression in those diseases. | |
II. Introduction | |
Expressed gene: | TIGIT/PVRIG |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800 ug/ml hygromycin+10ug/ml blasticidin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
III. Representative Data | |
Figure 1. Recombinant TIGIT/PVRIG Dual Effector Reporter Cell constitutively expressing TIGIT. Figure 2. Recombinant TIGIT/PVRIG Dual Effector Reporter Cell constitutively expressing PVRIG. | |
Figure 3. Dose Response of Blocking Antibodies in TIGIT/PVRIG Dual Effector Reporter Cells(C45) With CD112/CD155 Dual aAPC Cells. | |